



Global Health L i m i t e d

November 14, 2024

Ref:- GH/2024-25/EXCH/82

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Press Release

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release, for the second quarter and half year ended September 30, 2024 Results.

Kindly take the above on record.





Thanking you,

Yours faithfully

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a



Medanta delivered highest ever quarterly Revenue and EBITDA**Total Income of Rs. 9,748 million in Q2 FY25; up by 12.7% y-o-y and 10.4% q-o-q****EBITDA of Rs. 2,465 million, up by 5.5% y-o-y and 18.4% q-o-q****Net Profit of Rs. 1,308 million, up by 4.5% y-o-y and 23.1% q-o-q****Medanta enters into an agreement to operate and manage a state-of-the-art, 750-bed super-specialty hospital in Pitampura, New Delhi**

Gurugram, November 14th, 2024: Global Health Limited (NSE: [Medanta](#), BSE: [543654](#)), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announced its unaudited consolidated financial results for the quarter ending 30th September, 2024.

Consolidated Highlights Q2 FY2025

- Total income of Rs. 9,748 million, growth of 12.7% y-o-y and 10.4% q-o-q
- EBITDA was Rs. 2,465 million, growth of 5.5% y-o-y and 18.4% q-o-q. EBITDA margins were at 25.3% in Q2 FY25
- Profit after tax was Rs. 1,308 million, growth of 4.5% y-o-y and 23.1% q-o-q. PAT margins were 13.4% compared to 14.5% in Q2 FY24
- Net cash surplus of Rs. 7,186 million at the end of 30th September, 2024
- During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds in Q2 FY25
- Average occupied bed days increased by 9.1% y-o-y, with strong occupancy of 64.3% on increased bed capacity
- In-patients count increased by 8.8% y-o-y; Out-patients count increased by 6.6% y-o-y
- ARPOB marginally grew by 1.9% y-o-y to Rs. 62,140 in Q2 FY25 due to combination of tariff increase in Matured facility and change in case mix across the group
- Matured hospitals revenue was Rs. 6,882 million, strong growth of 13.5% y-o-y and 7.8% on q-o-q basis. EBITDA was Rs. 1,739 million, growth of 12.5% y-o-y and 9.4% on q-o-q basis
- Developing hospitals revenue was Rs. 2,754 million, growth of 4.2% y-o-y and 16.2% on q-o-q basis. EBITDA was Rs. 823 million, down by 8.2% y-o-y and strong growth of 41.7% on q-o-q basis
- During the quarter, International Patients Revenue was Rs. 513 million
- Out-patient pharmacy (Hospital + Retail) continues to register strong growth. Revenue increased by 24.5% from Rs. 298 million in Q2 FY24 to Rs. 371 million in Q2 FY25

Commenting on Q2 FY2025 results, Mr. Pankaj Sahni, Group CEO and Director said:

“We are pleased to report a strong performance this quarter, achieving our highest-ever quarterly Revenue and EBITDA. Growth momentum was robust across our network hospitals, as we continue to invest in cutting-edge technologies, enhance clinical capabilities through the on-boarding of senior clinicians, and expand our network by adding more beds.

I am also excited to announce that Medanta has recently signed an Operations and Management agreement to operate and manage a state-of-the-art, 750-bed super-specialty hospital in Pitampura, New Delhi. The hospital will be jointly built by Medanta and our partners Dr. Narayan Dutt Shirmali Foundation International Charitable Trust Society. This expansion reinforces our vision of creating a high-quality healthcare delivery platform, strengthens our presence in Delhi/NCR, and underscores our commitment to elevating patient care in the region through world-class services and infrastructure.”

Key Developments: Q2 FY2025

- During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds
- 25 doctors on-boarded across facilities to further strengthen clinical capability
- New Da Vinci Xi robot introduced in Lucknow and additional Da Vinci Xi robot operationalized in Gurugram
- Medanta Gurugram performed its first CAR-T Cell therapy, an advanced cancer treatment that harnesses the power of the patient’s own immune system to fight cancer
- Medanta Gurugram achieves significant milestone of completing 3,000 kidney transplants
- Medanta Lucknow completes 100 breast cancer surgeries
- Medanta Gurugram doctors successfully performed bilateral lung transplant in a patient with ILD and complex autoimmune condition
- Medanta Gurugram doctors uses minimally invasive unique approach to treat rare heart condition idiopathic chylopericardium
- Complex and severe genetic disorder Wiskott Aldrich Syndrome cured at Medanta Gurugram using half-match stem cell transplant

Financial Highlights: H1 FY2025 and Q2 FY2025

INR million	Half Year End			Quarter				
	H1 FY24	H1 FY25	Y-o-Y Growth %	Q2 FY24	Q1 FY25	Q2 FY25	Y-o-Y Growth %	Q-o-Q Growth %
Revenue from operations	16,300	18,176	11.5%	8,504	8,611	9,566	12.5%	11.1%
Other income	292	401	37.7%	142	219	182	27.9%	(16.9)%
Total income	16,592	18,578	12.0%	8,647	8,830	9,748	12.7%	10.4%
Cost of materials consumed	3,750	4,368	16.5%	1,936	2,089	2,280	17.8%	9.2%
Employee benefits expense	5,690	6,563	15.3%	2,912	3,197	3,366	15.6%	5.3%
Other expenses	2,823	3,099	9.8%	1,463	1,462	1,637	11.8%	11.9%
EBITDA	4,329	4,548	5.0%	2,336	2,082	2,465	5.5%	18.4%
EBITDA Margins %	26.1%	24.5%	(162) bps	27.0%	23.6%	25.3%	(173) bps	170 bps
Finance costs	380	340	(10.7)%	201	180	160	(20.5)%	(11.1)%
Depreciation and amortisation expense	833	960	15.3%	429	466	494	15.2%	6.0%
Profit before tax	3,116	3,248	4.2%	1,706	1,437	1,811	6.2%	26.1%
Tax expenses	845	877	3.8%	454	374	503	10.6%	34.5%
Profit after tax	2,272	2,371	4.4%	1,252	1,063	1,308	4.5%	23.1%

Note: Previous period figures have been regrouped/reclassified to conform to the current period's classification

About Global Health Limited (Medanta)

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the "Company") is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled "An assessment of the healthcare delivery market in India, September 2022" by CRISIL Limited.

Under the "Medanta" brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, and Patna). Spanning an area of 4.7 million sq. ft., its operational hospitals have 3,008 installed beds as on September 30, 2024. It also has one hospital under-construction in Noida. The Company provides healthcare services in over 30 medical specialties and engages over 1,750+ doctors led by highly experienced department heads.

For more information visit www.medanta.org or contact:

Global Health Limited

Ravi Gothwal

ravi.gothwal@medanta.org

Tel: 0124 – 4141 414

Bhushan Khandelwal

bhushan.khandelwal@medanta.org

Tel: 0124 – 4141 414

Safe Harbour Disclaimer

This press release, apart from historical information, contains some "forward-looking statements" including those describing the Company's strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.